The use of Traditional Chinese Medicines to treat SARS-CoV-2 may cause more harm than good

Gray, Paul; Belessis, Yvonne

doi:10.1016/j.phrs.2020.104776

Cited by 26 publications

(25 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the emerging scholarly efforts in addressing the safety concerns of the COVID-19 global emergency, a significant portion of the studies have understandably focused on aspects related to the safety of medicine, treatment and vaccines as one of the most urgent matters in battling this pandemic (Cellina et al, 2020;Gray and Belessis, 2020;Schlagenhauf et al, 2020;Sodhi and Etminan, 2020;Zhang, 2020;Zheng et al, 2020a). In doing so, many studies have synthesised the scientific evidence regarding the safety and efficacy of various treatments based on experiences obtained from previous pandemics of similar nature, such as SARS and MERS.…”

Section: Medicine Treatment and Vaccine Safetymentioning

confidence: 99%

The scientific literature on Coronaviruses, COVID-19 and its associated safety-related research dimensions: A scientometric analysis and scoping review

et al. 2020

View full text Add to dashboard Cite

Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre-including this research content-immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

show abstract

Section: Medicine Treatment and Vaccine Safetymentioning

confidence: 99%

The scientific literature on Coronaviruses, COVID-19 and its associated safety-related research dimensions: A scientometric analysis and scoping review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Its efficacy in alleviating acute respiratory distress syndrome caused by SARS-CoV-2 has been endorsed by both Chinese regulatory agency and the healthcare workers on the frontline. Recent perspectives from academics argued that the potential of herbal medicine to be an appropriate therapy for COVID-19 was open to question in the context that the pharmacological mechanism of those herbs remains unclear and hard to be fully explored (Gray and Belessis, 2020;Tao et al, 2020). That said, it is still undeniable that empirical therapy of herbal medicines contributed to the successful arrest of COVID-19 spreading in China to some extent, based on clinical observation.…”

Section: Herbal Medicines Alleviating Acute Respiratory Infectionmentioning

confidence: 99%

Current Prevention of COVID-19: Natural Products and Herbal Medicine

et al. 2020

View full text Add to dashboard Cite

Starting from December 2019, novel coronavirus disease 2019 (COVID-19) pandemic has caused tremendous economic loss and unprecedented health crisis across the globe. While the development of cure is at full speed, less attention and fewer effort have been spent on the prevention of this rapidly spreading respiratory infectious disease. Although so far, several vaccine candidates have advanced into clinical trials, limited data have been released regarding the vaccine efficacy and safety in human, not mention the long-term effectiveness of those vaccines remain as open question yet. Natural products and herbal medicines have been historically used for acute respiratory infection and generally show acceptable toxicity. The favorable stability for oral formulation and ease of scaling up manufacture make it ideal candidate for prophylactic. Hereby, we summarized the most recent advance in SARS-CoV-2 prevention including vaccine development as well as experimental prophylactics. Mainly, we reviewed the natural products showing inhibitory effect on human coronavirus, and discussed the herbal medicines lately used for COVID-19, especially focused on the herbal products already approved by regulatory agency with identifiable patent number. We demonstrated that to fill in the response gap between appropriate treatment and commercially available vaccine, repurposing natural products and herbal medicines as prophylactic will be a vigorous approach to stop or at least slow down SARS-CoV-2 transmission. In the interest of public health, this will lend health officials better control on the current pandemic.

show abstract

“…27 Furthermore, a vast array of (not yet evidence-based) therapeutic options have been utilised in many of these descriptive studies, including antiviral agents, traditional medicine, antibiotics, and immunomodulatory agents, many of which have known adverse effects, further complicating the ability to ascertain whether complications in these cases were due to SARS-CoV-2 or other factors implicated in these presentations. 36,37 The direct long-term outcomes for children from SARS-CoV-2 infection remains to be seen. Aside from the multisystem inflammatory sequelae potentially associated with SARS-CoV-2 (see section Multisystem inflammatory sequelae) there are no outcome data for children with SARS-CoV-2 infection beyond acute infection.…”

Section: Spectrum Of Diseasementioning

confidence: 99%

SARS-CoV-2 in children: spectrum of disease, transmission and immunopathological underpinnings

et al. 2020

Self Cite

View full text Add to dashboard Cite

As the SARS-CoV-2 pandemic unfolds across the globe, consistent themes are emerging with regard to aspects of SARS-CoV-2 infection and its associated disease entities in children. Overall, children appear to be less frequently infected by, and affected by, SARS-CoV-2 virus and the clinical disease COVID-19. Large epidemiological studies have revealed children represent less than 2% of the total confirmed COVID-19 cases, of whom the majority experience minimal or mild disease that do not require hospitalisation. Children do not appear to be major drivers of SARS-CoV-2 transmission, with minimal secondary virus transmission demonstrated within families, schools and community settings. There are several postulated theories regarding the relatively low SARS-CoV-2 morbidity and mortality seen in children, which largely relate to differences in immune responses compared to adults, as well as differences in angiotensin converting enzyme 2 distribution that potentially limits viral entry and subsequent inflammation, hypoxia and tissue injury. The recent emergence of a multisystem inflammatory syndrome bearing temporal and serological plausibility for an immunemediated SARS-CoV-2-related disease entity is currently under investigation. This article summarises the current available data regarding SARS-CoV-2 and the paediatric population, including the spectrum of disease in children, the role of children in virus transmission, and host-virus factors that underpin the unique aspects of SARS-CoV-2 pathogenicity in children.

show abstract

The use of Traditional Chinese Medicines to treat SARS-CoV-2 may cause more harm than good

Cited by 26 publications

References 7 publications

The scientific literature on Coronaviruses, COVID-19 and its associated safety-related research dimensions: A scientometric analysis and scoping review

The scientific literature on Coronaviruses, COVID-19 and its associated safety-related research dimensions: A scientometric analysis and scoping review

Current Prevention of COVID-19: Natural Products and Herbal Medicine

SARS-CoV-2 in children: spectrum of disease, transmission and immunopathological underpinnings

Contact Info

Product

Resources

About